Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (131-140 of 221) with videos related to

Pageof 23
Sort By:
JTO Clinical and Research Reports|January 6, 2025
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?J Humberto Rodriguez-Quintero, Rajika Jindani, Roger Zhu, et al.
Cytojournal|July 3, 2014
Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samplesJonas J Heymann, William A Bulman, Roger A Maxfield, et al.
Molecular and Cellular Biology|January 24, 2006
Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in miceDaniela S Bassères, Elena Levantini, Hongbin Ji, et al.
Future Oncology (London, England)|August 3, 2019
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancerThomas J Lynch, David Fenton, Vera Hirsh, et al.
Cancer Research|July 3, 2008
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancerGuosheng Huang, Rosana Eisenberg, Min Yan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 26, 2021
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancerHaiying Cheng, Yiyu Zou, Chirag D Shah, et al.
Journal of Clinical Medicine|May 1, 2019
Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung CancerKunal R Chaudhary, Sherry X Yan, Samuel P Heilbroner, et al.
NPJ Precision Oncology|January 27, 2026
Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLCMatthew Lee, Junmin Song, Emily Miao, et al.
Future Oncology (London, England)|October 20, 2018
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Pageof 23

Showing results (131-140 of 221) with videos related to

Sort By:
Pageof 23
JTO Clinical and Research Reports|January 6, 2025
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?J Humberto Rodriguez-Quintero, Rajika Jindani, Roger Zhu, et al.
Cytojournal|July 3, 2014
Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samplesJonas J Heymann, William A Bulman, Roger A Maxfield, et al.
Molecular and Cellular Biology|January 24, 2006
Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in miceDaniela S Bassères, Elena Levantini, Hongbin Ji, et al.
Future Oncology (London, England)|August 3, 2019
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancerThomas J Lynch, David Fenton, Vera Hirsh, et al.
Cancer Research|July 3, 2008
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancerGuosheng Huang, Rosana Eisenberg, Min Yan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 26, 2021
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancerHaiying Cheng, Yiyu Zou, Chirag D Shah, et al.
Journal of Clinical Medicine|May 1, 2019
Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung CancerKunal R Chaudhary, Sherry X Yan, Samuel P Heilbroner, et al.
NPJ Precision Oncology|January 27, 2026
Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLCMatthew Lee, Junmin Song, Emily Miao, et al.
Future Oncology (London, England)|October 20, 2018
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Pageof 23